INFECTIOUS DISEASES SOCIETY OF AMERICA for INFECTIOUS DISEASES SOCIETY OF AMERICA
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Creation of tax credits to incentivize R&D of new antibiotics for serious and life threatening drug-resistant infections (generally, no specific legislation); related new rapid diagnostic tests (generally, no specific legislation).
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMANDA JEZEK | V.P. Public Policy & Government Relations |
| JONATHAN NURSE | Government Relations Director |
Health Issues HCR
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMANDA JEZEK | V.P. Public Policy & Government Relations |
| KIMBERLY ANN MILLER | HIV Medicine Association Policy Officer |
| JONATHAN NURSE | Government Relations Director |
Medicare/Medicaid MMM
Reimbursement for outpatient infusion therapy (generally, no specific legislation); physician payments (generally, no specific legislation); Medicaid and Medicare, including Medicare Prescription Drug Coverage (generally, no specific legislation); Average Sales Price (generally, no specific legislation); Competitive Acquisition Program (generally, no specific legislation); infection control (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); Healthcare Reform (generally, no specific legislation).
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMANDA JEZEK | V.P. Public Policy & Government Relations |
| KIMBERLY ANN MILLER | HIV Medicine Association Policy Officer |
| JONATHAN NURSE | Government Relations Director |
Budget/Appropriations BUD
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMANDA JEZEK | V.P. Public Policy & Government Relations |
| KIMBERLY ANN MILLER | HIV Medicine Association Policy Officer |
| JONATHAN NURSE | Government Relations Director |
Medical/Disease Research/Clinical Labs MED
Medical liability (generally, no specific legislation); antimicrobial resistance research (generally, no specific legislation); infectious diseases product R&D (generally, no specific legislation); regulatory science (generally, no specific legislation); unnecessary regulatory burdens placed on medical research (generally, no specific legislation); laboratory developed tests (generally, no specific legislation); comparative effectiveness research (generally, no specific legislation); support for evidence-based decision making (generally, no specific legislation); point-of-care diagnostic tests (generally, no specific legislation); and organ transplant policy to allow HIV+ to HIV+ organ transplants (generally, no specific legislation).
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMANDA JEZEK | V.P. Public Policy & Government Relations |
| KIMBERLY ANN MILLER | HIV Medicine Association Policy Officer |
| JONATHAN NURSE | Government Relations Director |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.